Rituximab in chronic lymphocytic leukemia
- 28 February 2003
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 30 (1) , 34-39
- https://doi.org/10.1053/sonc.2003.50033
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trialSeminars in Oncology, 2002
- Rituximab: Ongoing and future clinical developmentSeminars in Oncology, 2002
- Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen speciesBlood, 2001
- Rituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood, 2001
- European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic LymphomaJournal of Clinical Oncology, 2000
- Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphomaAnnals of Oncology, 1998
- Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial TherapyBlood, 1998
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1997
- Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemiaThe Lancet, 1996